August 24, 2017 09:14 AM EDTUpdated 10:18 AM
News Briefing

Trou­bled Im­muno­Cel­lu­lar slash­es costs, jobs in re­struc­tur­ing; Ac­cel­er­at­ed Phar­ma dumps strug­gling IPO ef­fort

Shehla Shakoor

Managing Director

⇨ LA-based Im­muno­Cel­lu­lar Ther­a­peu­tics $IMUC is push­ing through a cost-cut­ting pro­gram, slash­ing staff and fa­cil­i­ties in the process. Two board mem­bers are al­so leav­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times